(Q33384544)

English

A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL.

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL. (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yukio Kobayashi

object named as

Yukio Kobayashi

5

0 references

Kazuma Ohyashiki

7

object named as

Kazuma Ohyashiki

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1

object named as

Arinobu Tojo

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

18

object named as

Noriko Usui

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Kensuke Usuki

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Akio Urabe

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yasuhiro Maeda

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Itsuro Jinnai

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Miki Nishimura

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Tatsuya Kawaguchi

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hideo Tanaka

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Koichi Miyamura

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yasushi Miyazaki

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Timothy Hughes

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Susan Branford

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Shinichiro Okamoto

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jun Ishikawa

16

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Masaya Okada

17

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hiromi Tanii

19

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Taro Amagasaki

20

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hiroko Natori

21

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Tomoki Naoe

22

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

19 May 2009

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

International Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

89

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

679-688

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449194

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Staging and prognosis in chronic myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449194

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449194

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449194

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The biology of chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449194

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449194

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449194

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449194

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449194

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449194

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12185-009-0327-0

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33384544&oldid=2195308093"